Streetbeat News

Assets

SDOT

Sadot Group Inc. (NASDAQ:SDOT) announced the sale of Superfit Foods LLC, a subscription-based meal prep concept located in Orange Park, FL. The terms of the sale were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 1:20 pm

MULN

Mullen Automotive has announced that it has met all federal and state regulatory requirements for its Class 1 and Class 3 commercial vehicles. The company is actively manufacturing and selling these vehicles across the US. Mullen's total assets are expected to be approximately $191.4 million as of June 30.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:03 pm

PTGX

Protagonist Therapeutics (PTGX) reported having $595.4 million in cash and equivalents as of June 30, 2024, which is expected to provide a cash runway through the end of 2027.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:53 am

SNSE

Sensei Biotherapeutics reported having $52.3 million in cash, cash equivalents, and marketable securities as of June 30, 2024. This funding is expected to support operations into the fourth quarter of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:48 am

BDTX

Black Diamond Therapeutics (BDTX) reported having $123 million in cash, cash equivalents, and investments as of June 30, 2024. This amount is expected to be sufficient to fund its operations into the fourth quarter of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:45 am

ADCT

ADC Therapeutics reported having $300.1 million in cash and cash equivalents as of June 30, which extends their expected cash runway into mid-2026.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:37 am

NMRA

Neumora Therapeutics has $371.6 million in cash, cash equivalents, and marketable securities, which is expected to support its operations into 2026.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:27 am

ELEV

Elevation Oncology announced that its existing cash, cash equivalents, and marketable securities totaling $110.8 million as of June 30, 2024, are expected to be sufficient to fund its current operations into 2026.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:25 am

TENX

Tenax Therapeutics has secured $100 million in an oversubscribed private placement financing led by BVF Partners LP, with participation from several other new investors.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:16 am

TGTX

On August 2, 2024, TG Therapeutics entered into a $250 million term loan facility with Blue Owl Capital.

Portfolio Pulse from charles@benzinga.com

August 06, 2024 | 11:11 am